News + Font Resize -

New Pfizer Animal Health is unveiled with acquisition of Wyeth
New York | Wednesday, October 21, 2009, 08:00 Hrs  [IST]

A new Pfizer Animal Health was unveiled last week as Pfizer's acquisition of Wyeth, including its subsidiary Fort Dodge Animal Health, was completed. Pfizer Animal Health is now the world's leader in the discovery, development, manufacture and sales of veterinary vaccines and medicines for livestock and companion animals.

The acquisition of many of Fort Dodge's US products allows Pfizer Animal Health to greatly diversify its US portfolio, as well as broaden its offering in all animal health segments. Pfizer Animal Health now offers an enhanced portfolio in beef, dairy, and companion animals, as well as a redefined product line for swine, equine and poultry.

"We're extremely proud to offer our customers even more best-in-class and innovative products," said Clint Lewis, president of US Operations for Pfizer Animal Health. "The products, services and expertise we are gaining strengthen what is already a robust US portfolio and will enhance our leading position in the animal health marketplace."

Pfizer Animal Health also announced that all current US pricing, product distribution, programmes and policies for Pfizer Animal Health products, including the acquired Fort Dodge products, will remain in place through 2009.

"Pfizer Animal Health is passionate about working hand-in-hand with our customers and partners to transform the care, health and well-being of animals," Lewis said. "We continue to envision a future where animal health care providers, veterinarians and livestock producers look to Pfizer first to help them to run their practice or operation productively and profitably. With our newly expanded portfolio, value-added services and high-caliber talent, Pfizer is more focused than ever on providing relevant solutions to their animal care needs," Lewis said.

Pfizer Animal Health, a business of Pfizer Inc, is a world leader in discovering and developing innovative animal prescription medicines and vaccines, investing an estimated US$ 300 million annually.

Post Your Comment

 

Enquiry Form